Autologous chondrocyte transplantation is nothing new. In studies published by Brittberg et al. in 1994, clinical application of autologous chondrocytes for treating cartilage defects was proven in over 5000 cases. The findings of medium- and long-term studies are particularly promising for patients who have undergone unsuccessful cartilage treatment in the past. A feature of the original technique was the injection of chondrocyte suspension into the interior of a “bioactive chamber ” under a periosteal flap (so called 1st generation ACI).
The 2nd generation ACI improved this technique by injecting the cultured cells directly into a collagen or gel-like membrane. This method prevents chondrocytes from dispersing in the joint but does not offer primary stability because of the unstable scaffold structure.
The solution: BioSeed®-C, the stable 3rd Genration ACI
Based on the unique technology of BioTissue, cells can not only be distributed three-dimensionally, but an exclusive form- and shape stability has been achieved. This has resulted in optimal differentiation of the cultured chondrocytes and has led to a standardised implantation technique.
A unit of BioSeed®-C consists of a three-dimensional cartilage grafts with 28.8 millions cells.
BioSeed®-C is completely biocompatible and consists of surgical, resorbable suture material with interconnecting cavities (over 90 % of the total volume). This structure is ideal for 3D homogenous chondrocytes distribution since the chondrocyte phenotype remain differentiated.
Due to the properties of the carrier fleece, BioSeed®-C has perfect biocompatibility and excellent primary mechanical stability which allows to fix the scaffold in a secure way.
BioSeed®-C is the result of years of research carried out by Berlin Charité University of Medicine and by Freiburg University Hospital.